ClinicalTrials.gg
RecruitingNCT06017362Updated Oct 22, 2024

Clinical Trial to Determine the Efficacy and Safety of Insulin Eye Drops in Dry Eye in Patients with Topical Hypotensors

A Phase 4 interventional study of Insulin and Artificial tear in Dry Eye and Glaucoma, sponsored by Barbara Burgos Blasco. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-22.

Sponsored by Barbara Burgos Blasco · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Feb 2023, registered Aug 2023).
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Dry Eye Syndromes with a site in Spain — 3 open to participants now, 4 under way, none of them phase 3. Dry Eye Syndromes · Spain.

Planned enrollment
11th of 41
100 · median 60
Started
2023
with 3 others
Phase 4
5 of 44
2 open now
Registered
31st of 44
by date
Lead sponsor
2 of 44
Barbara Burgos Blasco

Among the 44 studies in Dry Eye Syndromes with a site in Spain, this one is the 11th largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2023, is one of 5 in phase 4, and was the 31st registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 44 studies in Dry Eye Syndromes with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Dry Eye Syndromes with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the preliminary efficacy of the use of insulin eye drops in the control of dry eye disease in patients with topical hypotensors, compared to placebo (artificial tears).

The main question aims to answer whether glaucoma patients treated with topical hypotensors could benefit from the use of insulin eye drops for the treatment of dry eye.

Participants will be assigned to one of the two treatment arms and will be required to attend four follow-up visits (baseline, 1, 3, and 6 months).

Read the detailed description

Patients will be recruited in Madrid. Patients with dry eye disease and topical glaucoma treatment will be identified through the Ophthalmology clinic. They will be directly referred to a physician who is participating in this study.

03

Conditions studied

  • Dry Eye
  • Glaucoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who provide written and who are able and willing to comply with all scheduled study visits and procedures.
  • Patients ≥ 18 years at the screening visit.
  • Ocular hypertension or glaucoma controlled with hypotensive treatment
  • Diagnosis of dry eye

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled glaucoma with expected changes in antihypertensive treatment in the next 6 months
  • Changes in topical glaucoma treatment in the last 3 months
  • Severe dry eye requiring immediate treatment
  • Previous eye surgery, except cataract surgery more than 12 months ago
  • Laser procedures less than 6 months ago
  • Other concomitant ocular pathology: scarring disease of the ocular surface, uveitis, infection in the last 90 days, trauma in the last 90 days
  • Eyelid disorders
  • Use of contact lenses
  • Other topical treatment other than dry eye and glaucoma
  • Patients with a history of allergy or to the study medication or any of its
  • Modifications in systemic treatment in the last 6 months
  • History of alcohol or drug abuse
  • Patients who have received an experimental drug or used an experimental medical device in the 30-day period prior to the screening visit.
  • Systemic pathology (cardiopulmonary pathology, connective tissue disorders, neurological or psychiatric pathology) or situation of the patient that does not allow examination (such as mental or psychomotor retardation).
  • Any other disease or condition that, at the discretion of the investigator, could constitute a risk to the participant or interfere with the results of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Insulin

    Topical insulin 1UI/ml 4 times a day

    Drug: Insulin

  • Placebo comparator
    Placebo (artificial tears)

    Artificial tears 4 times a day

    Drug: Artificial tear

Interventions

  • Topical insulin 1UI/ml 4 times a day

  • DrugArtificial tear

    Artificial tears 4 times a day

06

What researchers measure

Primary outcomes

  1. Changes in dry eye symptoms from baseline to 6 months after treatment time

    Dry eye symptoms will be evaluated using OSDI

    Time frame: From baseline to 6 months after treatment

Secondary outcomes

  1. Change of corneal staining from baseline to 6 months after treatment

    Corneal staining will be evaluated on the slit-lamp and on slit-lamp images

    Time frame: From baseline to 6 months after treatment

  2. Change in corneal aesthesiometry from baseline to 6 months after treatment

    Aesthesiometry will be evaluated using Cochet Bonnet

    Time frame: From baseline to 6 months after treatment

  3. Change in conjunctival hyperemia from baseline to 6 months after treatment

    Conjunctival hyperemia will be evaluated using Keratograph

    Time frame: From baseline to 6 months after treatment

  4. Change in non-invasive tear film break-up time from baseline to 6 months after treatment

    Non-invasive tear film break-up time will be evaluated using Keratograph

    Time frame: From baseline to 6 months after treatment

  5. Change in light dispersion from baseline to 6 months after treatment

    Light dispersion will be evaluated using the Optical Quality Analysis System

    Time frame: From baseline to 6 months after treatment

  6. Change in cytokine levels from baseline to 6 months after treatment

    Cytokine leves will be evaluated using immunoassay

    Time frame: From baseline to 6 months after treatment

  7. Change in therapeutic compliance from baseline to 6 months after treatment

    Therapeutic compliance will be evaluated using Medication adherence rating scale (MARS). The total score ranges from 0-10 with a higher score indicating better adherence.

    Time frame: From baseline to 6 months after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Feb 2026, 36 months after the start.

Of 85 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 36 months is above that.

Counting every sponsor, half of 113 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2023
First posted
Aug 30, 2023
StartActual
Feb 8, 2023
Primary completionEst.
Feb 8, 2026
CompletionEst.
Feb 8, 2026
Last update
Oct 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06017362
Lead sponsor
Barbara Burgos Blasco
Responsible party
Barbara Burgos Blasco (Principal Investigator, Hospital San Carlos, Madrid) — Sponsor-investigator
First posted
Aug 30, 2023
Start date
Feb 8, 2023
Primary completion
Feb 8, 2026 (estimated)
Completion
Feb 8, 2026 (estimated)
Last update
Oct 22, 2024

Study contacts

Barbara Burgos Blasco, MD, PhD
Contact
bburgos171@hotmail.com
+34 913303000 ext. 3132
Barbara Burgos Blasco, MD, PhD
principal investigator · Hospital Clinico San Carlos

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion